Q-omics provides the consensus-scored SCHIP1 profile across patient tissues and cancer cell-line models. SCHIP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SCHIP1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, SCHIP1 RNA expression shows 19,665 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KICH, and GBM as cancer lineages where SCHIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCHIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCHIP1 survival associations across molecular data types. SCHIP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCHIP1 RNA expression–survival associations across cancer types. High SCHIP1 expression shows unfavorable associations in UCEC, MESO, COAD, SCLC and LAML, but favorable associations in LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SCHIP1 RNA expression.
This table summarizes SCHIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SCHIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCHIP1 shows lower tumor expression in KICH, LUAD, COAD, BRCA and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher SCHIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.184, t-test p < 0.001).
This table shows molecular features associated with SCHIP1 in patient tissues and cancer cell lines. In patient samples, SCHIP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCHIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
